Sharemaestro company-news research for Glenmark Pharmaceuticals Limited (GLENMARK), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NSI
India
Provisional evidence
Company news sentiment
Latest GLENMARK news and sentiment
Glenmark Pharmaceuticals Limited
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
8 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone35/100
→
Published 30-day score49/100
Latest source headline
Glenmark Pharmaceuticals stock fell 2.36% on October 5
AD HOC NEWS · 05 Oct 2026 08:57
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
8 current stories are mapped specifically to GLENMARK.
What limits the score
Only 2 publishers currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.034.
Confidence is 20/100, below the threshold for a firm score.
49/100
News scoreEarly balanced news score
20/100
Confidencethin evidence
100%/100
Company news8 company stories
98/100
Story agreement2/100 difference
News history
Daily score and story count over 30 days
10 Sep25 Sep09 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.034 after freshness weightingSource breadth40
2 independent publishersCompany relevance100
share tied directly to this companyFreshness35
recency-weighted evidenceAgreement98
how closely stories agreePublisher mix2
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
10 Apr07 Jul02 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
02 Oct 202650INR 2331.0-2.1%
25 Sep 202650INR 2380.0-2.8%
18 Sep 202650INR 2447.399902+1.2%
11 Sep 202650INR 2419.199951-0.7%
04 Sep 202650INR 2437.199951-3.0%
28 Aug 202650INR 2512.5+8.5%
21 Aug 202651INR 2315.595947+0.0%
14 Aug 202651INR 2316.095459+1.7%
Provisional evidence
News subjects
What is shaping the score
Market update395 stories · 62%
Earnings503 stories · 38%
Source mix
Where the evidence comes from
scanx.trade503 stories · 38%
AD HOC NEWS392 stories · 25%
Business Standard571 stories · 12%
Univest501 stories · 12%
siam.in501 stories · 12%
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
20 Jun50 neutral07 Oct 02:32
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 07 Oct 02:32 | 49 | +0 | 24/100 (-4) | 8 (-2) | Provisional |
| 05 Oct 23:59 | 49 | -1 | 28/100 (+13) | 10 (+1) | Provisional |
| 04 Oct 23:59 | 50 | +0 | 15/100 (-1) | 9 (0) | Provisional |
| 29 Sep 23:59 | 50 | +0 | 16/100 (-8) | 9 (-2) | Provisional |
| 23 Sep 23:59 | 50 | +0 | 24/100 (-3) | 11 (+1) | Provisional |
| 22 Sep 23:59 | 50 | +0 | 27/100 (+12) | 10 (0) | Provisional |
| 15 Sep 23:59 | 50 | +0 | 15/100 (0) | 10 (+2) | Provisional |
| 13 Sep 23:59 | 50 | +0 | 15/100 (0) | 8 (0) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 8 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Market update2 stories
99.1%0.9%
Each side uses the same scale: 0–99.1% of the retained directional evidence.
Where the influence comes from
99.1%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
35/100 tone
Market update
Glenmark Pharmaceuticals stock fell 2.36% on October 5
99.1% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 05 Oct 2026 08:57
- News subject
- Market update
- Why this score
- Negative market reaction, Large negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 47/100
- 30-day weight
- 99.1% of directional evidence · 3.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Glenmark Pharmaceuticals stock weighs Q1 growth against a Hold call
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 04 Oct 2026 12:46
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 4.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Glenmark targets 13-15% revenue CAGR, 23% EBITDA margin by FY27; Investec maintains Buy
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 29 Sep 2026 23:03
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Glenmark Pharmaceuticals Stock Signals to Watch This Week
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 23 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
57/100 tone
0.9% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 22 Sep 2026 07:00
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 0.9% of directional evidence · 17.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Glenmark uploads Q4FY26 earnings call transcript
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 15 Sep 2026 18:15
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Glenmark targets 13-15% revenue CAGR, 23% EBITDA margin by FY27; Investec maintains Buy
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 15 Sep 2026 17:53
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Glenmark Pharmaceuticals (GLENMARK.NS) Edges Higher to ₹2,419.2 as Stock Consolidates Below ₹2,540 Resistance - OBV Breakout
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 13 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
GLENMARK news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 32 older GLENMARK headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to GLENMARK, but the headline and available text are not mainly about Glenmark Pharmaceuticals Limited. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of GLENMARK sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.